


## RN-18

Cat. No.:	HY-102014		
CAS No.:	431980-38-0		
Molecular Formula:	C <sub>20</sub> H <sub>16</sub> N <sub>2</sub> O <sub>4</sub> S		
Molecular Weight:	380.42		
Target:	HIV		
Pathway:	Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (262.87 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.6287 mL	13.1434 mL	26.2867 mL
	5 mM	0.5257 mL	2.6287 mL	5.2573 mL
	10 mM	0.2629 mL	1.3143 mL	2.6287 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

RN-18 is a HIV-1 viral infectivity factor (HIV-1 Vif) inhibitor with an IC<sub>50</sub> of 6 μM in nonpermissive H9 cells.

#### IC<sub>50</sub> & Target

IC<sub>50</sub>: 6 μM (nonpermissive H9 cell)<sup>[1]</sup>

#### In Vitro

RN-18 and RN-19 exhibits potent antiviral activity in the nonpermissive H9 and CEM cells but not in MT4 or CEM-SS cells, confirming that the antiviral activity was Vif specific. RN-18 shows the greater potency (IC<sub>50</sub>=4.5 μM in CEM cells) and specificity (IC<sub>50</sub>>100 μM in MT4 cells) among the two compounds<sup>[1]</sup>. In the presence of the inhibitor, RN-18, reverse transcriptase activity in the nonpermissive H9 and CEM cells decreases substantially and in a dose-dependent manner. RN-18 also exhibits antiviral activity in CEM-SS modified to stably express A3G but does not exhibit antiviral activity in the parental CEM-SS cell line. RN-18 antagonizes Vif function and inhibits HIV-1 replication only in the presence of A3G. RN-18 increases cellular A3G levels in a Vif-dependent manner and increases A3G incorporation into virions without inhibiting general proteasome-mediated protein degradation. RN-18 enhances Vif degradation only in the presence of A3G, reduces viral infectivity by increasing A3G incorporation into virions and enhances cytidine deamination of the viral genome<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## PROTOCOL

### Cell Assay [2]

H9 or MT4 cells are treated overnight with 0, 1, 5, 10, 25 or 50  $\mu$ M RN-18 (all at 0.1% DMSO) and infected with HIV-1. All cells are maintained in the presence of DMSO or RN-18 for 14 d, and viral replication is monitored every 2 d by measuring reverse transcriptase activity in culture supernatants. The average % relative infectivity at day 7 is determined from 3 separate reverse transcriptase assays. Grafit software is used to fit curves and to determine  $IC_{50}$  [2].  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

- [1]. Mohammed I, et al. SAR and Lead Optimization of an HIV-1 Vif-APOBEC3G Axis Inhibitor. ACS Med Chem Lett. 2012 Jun 14;3(6):465-469.  
[2]. Nathans R, et al. Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol. 2008 Oct;26(10):1187-92.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA